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Hereditary Breast and Ovarian Cancer Syndrome
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome is an inherited genetic condition
that occurs due to a mutation in either the BRCA1 or BRCA2 gene. Normal BRCA (BReast
CAncer) genes protect against the development of certain types of cancer. If these genes
mutate and do not function correctly a person’s lifetime risk of developing breast and /or
ovarian cancer is increased. Women who are BRCA positive (meaning that they have an
inherited BRCA mutation) have up to an 85 percent lifetime risk of developing breast cancer
and up to a 44 percent lifetime risk of developing ovarian cancer. Genetic testing can help to
identify people with BRCA gene mutations. About 1 out of every 20 breast cancers (5%) is
caused by a BRCA gene mutation and about 1 out of every 10 ovarian cancers (10%) is
caused by a BRCA gene mutation.
Of importance, many BRCA-associated breast cancers occur under the age of 40 or 50,
when regular screening is not being performed. Men who are BRCA positive also have up
to a 6 percent lifetime risk of developing breast cancer and also an increased risk for
prostate cancer. It is well established that genetic testing for hereditary cancer syndromes
can improve patient outcomes by facilitating early detection of cancer, identifying effective
therapies, or in some cases, preventing disease altogether through prophylactic surgery.
The Georgia Breast Cancer Genomics Consortium
In 2011, the Georgia Department of Public Health was awarded funding from the Centers of
Disease Control and Prevention (CDC) to target young women ages 18 to 49, at high risk for
developing breast cancer, through counseling and testing for the genes that normally protect
against breast and ovarian cancer. The overarching goal of the initiative is to promote the
use of evidence-based guidelines to improve the identification of young women at genetic
risk for breast and ovarian cancer, with the ultimate goal of reducing the cancer burden in
this population and in disparate sub-populations. The three main areas of focus are
education, surveillance, and policy.
The Georgia Breast Cancer Genomics Consortium (Consortium) is in the third year of
implementing its three-year action plan to increase understanding and utilization of
appropriate genetic assessment and screening services within three targeted groups:
private and public health clinicians/practitioners, payers/policy makers, and young women at
risk. The Consortium is comprised of representatives the Georgia Department of Public
Health, Georgia Center for Oncology Research and Education, Inc. (Georgia CORE), Emory
University, Morehouse School of Medicine, and Georgia State University.
The following table is a summary of HBOC screenings facilitated by the work of the
Consortium.
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Public Health Clinics Currently Screening with B-RST Tool1
Clients Screened to Date (all sites)
Clients Screened Positive to Date (all sites)
Clients Who Have Agreed to Follow-Up to Date (all sites)
Clients Tested to Date
Positive Results (to date):
BRCA 1/2 Positive
Genetic Variant of Uncertain Significance
Unique Visitors to BreastCancerGeneScreen.org to Date3
Average Visitors per Day
1
2

8
2,602
154
143
16
1
1
5,846
40

Statistics reported as of April 11, 2014
Since May 2013

U.S. Preventive Services Task Force Recommendation
In December 2013, the U.S. Preventive Services Task Force (USPSTF) released its final
recommendation statement for Risk Assessment, Genetic Counseling, and Genetic Testing
for BRCA-Related Cancer in Women. The USPSTF has designated BRCA-related genetic
counseling and testing as a level B recommendation. In its statement, the USPSTF
recommended that primary care providers screen women with a family history of breast or
ovarian cancer for the BRCA1 or BRCA2 gene mutations via one of several screening tools.
One of the tools recommended was the Referral Screening Tool (B-RST), developed by
Consortium member Cecelia Bellcross. The B-RST tool was recognized as one of two
screening tools found to be “the simplest and quickest to administer”. The tool is located at
BreastCancerScreenGene.org.
In addition to pointing to the efficiency of the B-RST tool, the USPSTF also cited the need
for genetic counseling for women with positive screening results. Pre-and post-testing
counseling are critical to the entire process as it gives patients opportunities to further
understand their risk, get answers to their questions, voice concerns, and access resources
that aid in making informed decisions about their follow-up care.
Health Plan Coverage in Georgia
BRCA testing costs can range from $900 to $2900, making it financially inaccessible to
some patients. Genetic counseling is critical for patients to adapt to the medical,
psychological, and familial implications of disease and is essential to maximize costeffectiveness and quality of care. Many providers are not equipped to provide thorough
genetic counseling, thereby creating barriers to accessing these services. These barriers
can be reduced with expertly crafted health plan genetic testing policies and by increasing
members’ access to trained genetics experts who can improve cost-effectiveness by
ensuring BRCA testing is appropriate, the right test is ordered, and the right person in the
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family is tested. With the increasing prevalence of genetic testing, and reaffirmation of its
importance by the USPSTF, it is now a requirement for health plans and self-funded groups
to develop policies that address genetic counseling and testing.
Prior to the release of the 2013 final recommendations; an environmental scan of the eight
major health plans in Georgia revealed that most of the plans were clearly compliant with
the 2005 USPSTF recommendation that women at increased risk for BRCA mutations be
referred for genetic counseling and evaluation for BRCA testing1. Currently, 32 state
Medicaid programs cover genetic counseling and testing for HBOC for those who qualify.
To date, the Georgia Medicaid program does not cover genetic testing and counseling.
While Georgia’s private health insurers have been ahead of the curve in ensuring BRCArelated genetic counseling and testing for their members, there remains a gap in access for
the un- and underinsured. The Consortium is well positioned to be a resource to public and
private leadership for assistance and support in understanding and complying with policy
regulations to ensure that women in Georgia, especially those at high-risk for HBOC have
access to the services they require – services that will ultimately save both lives and money.
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The environmental scan was done in October 2013, at that time the most current USPSTF recommendation was
that released in 2005. The 2013 recommendation upholds the 2005 recommendation with regard to testing and
genetic counseling.
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